

## Weiterführende Literatur – Konsensus-Statement 2023 „Schizophrenie: Medikamentöse Therapie“

- Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. *Arch Gen Psychiatry* 2003; 60: 1228-35
- Alexopoulos GS, Streim JE, Carpenter D: Expert consensus guidelines for using antipsychotic agents in older patients. *J Clin Psychiatry* 2004; 65 (Suppl 2): 100-2
- American Psychiatric Association: The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia / Guideline Writing Group, Third edition. Washington, DC: American Psychiatric Association 2021
- Andreasen NC: The diagnosis of schizophrenia. *Schizophr Bull* 1987; 13(1): 9-22
- Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Gerlach M, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G; Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie: The AGNPTDM Expert Group Consensus Guidelines: therapeutic drug monitoring in psychiatry. *Pharmacopsychiatry* 2004; 37(6): 243-65
- Bäuml J, Pitschel-Walz G, Volz A, Lüscher S, Rentrop M, Kissling W, Jahn T: Psychoeducation improves compliance and outcome in schizophrenia without an increase of adverse side effects: a 7-year follow-up of the Munich PIP Study. *Schizophr Bull* 2016; 42 Suppl 1: 62-70
- Benkert O, Hippus H: *Kompodium der Psychiatrischen Pharmakotherapie*. 10. Auflage. Springer 2014
- Bramon E, McDonald C, Croft RJ et al.: Is the P300 wave an endophenotype for schizophrenia? A meta-analysis and a family study. *Neuroimage* 2005; 27: 960-8
- Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW: Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. *Biol Psychiatry* 2005; 57(10): 1117-27
- Conradi J, Jäger M, Kaiser S. Update: Negativsymptome. *Psychopathologie, Epidemiologie, Pathophysiologie und Behandlungsoptionen*. *Schweizer Archiv für Neurologie und Psychiatrie* 2013; 164(3): 77–84
- Correll CU, Citrome L, Haddad P, Lauriello J, Olfson M, Calloway S, Kane J: The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. *J Clin Psychiatry* 2016; 77: 1-24
- Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S, Debnath M, McGrath J, Maes M, Amminger P, McGorry PD, Pantelis C, Berk M: A review of vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. *Neurosci Biobehav* 2016; 65: 185-94
- DGPPN: S3-Leitlinie Psychosoziale Therapien bei schweren psychischen Erkrankungen. Heidelberg, Berlin: Springer 2019
- DGPPN e.V. (Hrsg.) für die Leitliniengruppe: S3-Leitlinie Schizophrenie. Langfassung, 2019, Version 1.0, zuletzt geändert am 15. März 2019, verfügbar unter: <https://www.awmf.org/leitlinien/detail/II/038-009.html>
- Dilling H, Mombour W, Schmidt MH: Internationale Klassifikation psychischer Störungen – ICD-10 Kapitel V (F), Klinisch-diagnostische Leitlinien, 10., überarbeitete Auflage, 2005; Hogrefe Verlag, Bern
- Dollfus S, Mucci A, Giordano GM, Bitter I, Austin SF, Delouche C, Erfurth A, Fleischhacker WW, Movina L, Glenthøj B, Gütter K, Hofer A, Hubenak J, Kaiser S, Libiger J, Melle I, Nielsen MØ, Papsuev O, Rybakowski JK, Sachs G, Üçok A, Brando F, Wojciak P, Galderisi S; European validation

of the self-evaluation of negative symptoms (sns): a large multinational and multicenter study. *Front Psychiatry* 2022; 13: 826465

- Essali A, Ali G: Antipsychotic drug treatment for elderly people with late-onset schizophrenia. *Cochrane Database Syst Rev* 2012; 2012(2): CD00416
- Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rössler A, Schultze-Lutter F, Keshavan M, Wood S, Ruhrmann S, Seidman LJ, Valmaggia L, Cannon T, Velthorst E, De Haan L, Cornblatt B, Bonoldi I, Birchwood M, McGlashan T, Carpenter W, McGorry P, Klosterkötter J, McGuire P, Yung A: The psychosis high risk state: A comprehensive state-of-the-art review. *JAMA Psychiatry* 2013; 70: 107-20
- Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, Lehrer D, Klein R, Hurst M: Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. *J Clin Psychiatry* 2016; 77(5): 661-7
- Gaebel W, Riesbeck M, Wobrock: Schizophrenia guidelines across the world: a selective review and comparison. *Int Rev Psychiatry* 2011; 23(4): 379-387
- Galling B, Vernon JA, Pagsberg AK, Wadhwa A, Grudnikoff E, Seidman AJ, Tsoy-Podosenin M, Poyurovsky M, Kane JM, Correll CU: Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia. *Acta Psychiatr Scand* 2018; 137(3): 187-205
- Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ: International consensus study of antipsychotic dosing. *Am J Psychiatry* 2010; 167(6): 686-93
- Gößler R: Psychopharmaka im Kindes- und Jugendalter. *Clinicum neuropsych* 2015; 2: 16-20
- Haddad PM, Correll CU: Long-acting antipsychotics in the treatment of schizophrenia: opportunities and challenges. *Expert Opin Pharmacother* 2023; 24(4): 473-493
- Hasan A, Wobrock T, Gaebel W, Janssen B, Zielasek J, Falkai P: Nationale und internationale Leitlinien zur Schizophrenie - Update 2013 zum Stand der Empfehlungen zur antipsychotischen Medikation. *Der Nervenarzt* 2013; 84: 1359-1368
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry* 2012; 13: 318-78
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry* 2013; 14: 2-44
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 3: update 2015 management of special circumstances: Depression suicidality substance use disorders and pregnancy and lactation. *World J Biol Psychiatry* 2015; 16: 142-70
- Howard R, Rabins PV, Seeman MV, Jeste DV: Late-onset schizophrenia and very-late-onset schizophrenia-like psychosis: An international consensus. *Am J Psychiatry* 2000; 157(2): 172-8
- Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu A, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Denning T, Knapp M, Romeo R, Gray R:

Amisulpride for very late-onset schizophrenia-like psychosis: the ATLAS three-arm RCT. *Health Technol Assess* 2018; 22(67): 1-62

- Huscsava M et al.: Österreichische Gesellschaft für Kinder- und Jugendpsychiatrie, Psychosomatik und Psychotherapie. Review über Psychopharmaka mit Zulassung in Österreich für die Anwendung an Kindern und/oder Jugendlichen. *Neuropsychiatr* 2020; 34(1): 1-4
- Iglewicz A, Meeks TW, Jeste DV: New wine in old bottle: late-life psychosis. *Psychiatr Clin North Am* 2011; 34(2): 295-318
- Jagsch C, Hofer A: Erkrankungen des schizophrenen Formenkreises im Alter. Diagnostische und therapeutische Herausforderungen. *Z Gerontol Geriat* 2018; 51: 744-50
- Jagsch C, Dietmaier G, Jagsch M, Kurz M: Diagnostik und medikamentöse Therapie bei schizophrenen Patienten im Alter. *Neuropsychiatrie* 2016. DOI 10.1007/s40211-016-0183-0.
- WHO (2021) Guidance on community mental health services: Promoting person-centred and rights-based approaches. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO
- Jalenques I, Rachez C, Tourtauchaux R, Cellier Y, Legrand G: Old patients suffering from long-standing schizophrenia: clinical aspects. *Geriatr Psychol Neuropsychiatr* 2011; 9(3): 345-53
- Jeste DV, Barak Y, Madhusoodanan S, Grossman F, Gharabawi G: International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. *Am J Geriatr Psychiatry* 2003; 11(6): 638-47
- Kapur S: Psychosis as a state of aberrant salience: a framework linking biology phenomenology and pharmacology in schizophrenia. *Am J Psychiatry* 2003; 160: 13-23
- Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M: Tardive dyskinesia: Analysis of outpatients with schizophrenia from Africa and the Middle East Asia Central and Eastern Europe and Latin America. *Schizophr Res* 2006; 139-43
- Kasper S, Baranyi A, Eisenburger P, Erfurth A, Ertl M, Frey R, Hausmann A, Kapfhammer HP, Psota G, Rados C, Roitner-Vitzthum E, Sachs GM, Winkler D: Die Behandlung der Agitation beim psychiatrischen Notfall. Konsensus-Statement – State of the Art 2013. *CliniCum neuropsychy, Sonderausgabe November 2013*
- Kasper, S Psota G, Erfurth A, Geretsegger C, Haring C, Hausmann A, Hofer A, Kapfhammer HP, Kastner A, Lehofer M, Marksteiner J, Naderi-Heiden A, Oberlerchner H, Praschak-Rieder N, Sachs GM, Stetter R, Walter E: Depot-Antipsychotika/-Neuroleptika. Konsensus-Statement – State of the Art 2014. *CliniCum neuropsychy, Sonderausgabe November 2014*
- Kasper S, Rainer M, Bacher R, Croy A, Fasching P, Fruhwürth G, Grunze H, Jagsch C, Jelem H, Kapfhammer H-P, Köller M, Lehofer M, Praschak-Rieder N, Psota G, Sachs G-M, Stastka K, Windhager E, Winkler A, Winkler D, Wuschitz A, Zauner K: Demenzerkrankungen: Medikamentöse Therapie. Konsensus-Statement – State of the Art 2015. *CliniCum neuropsychy, Sonderausgabe November 2015*
- Kasper S, Di Pauli J, Erfurth A, Geretsegger C, Kapfhammer HP, Papageorgiou K, Sachs GM, Wrobel M: Inhalatives Loxapin – Praxiserfahrungen nach dem ersten Anwendungsjahr. *CliniCum neuropsychy 2015*
- Khaldi S, Kornreich C, Choubani Z, Gourevitch R: Neuroleptic malignant syndrome and atypical antipsychotics: a brief review. *L'Encephale* 2008; 34 (6): 618–624
- Khouzam HR, Battista MA, Emes R, Ahles S: Psychoses in late life: evaluation and management of disorders seen in primary care. *Geriatrics* 2005; 60(3): 26-33
- Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested confirmed and extended. *Biol Psychiatry* 2005; 57(12): 1543-9
- Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J: The early stages of schizophrenia: speculations on pathogenesis pathophysiology and therapeutic approaches. *Biol Psychiatry* 2001; 50(11): 884-97

- McGrath J, Saha S, Chant D, Welham J: Schizophrenia: a concise overview of incidence prevalence and mortality. *Epidemiol Rev* 2008; 30: 67-76
- McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H et al.: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. *Neurology* 2005; 12: 1863-72
- Mei C, van der Gaag M, Nelson B et al.: Preventive interventions for individuals at ultra-high risk for psychosis: An updated and extended meta-analysis. *Clinical Psychology Review* 2021; 86: 102005
- Miller TJ, McGlashan TH, Rosen JL, et al. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. *Am J Psychiatry*. 2002;159(5):863–865
- Mukku SSR, Sivakumar PT, Varghese M: Clozapine use in geriatric patients – challenges. *Asian J Psychiatry* 2018; 33: 63-7
- Mucci A, Vignapiano A, Bitter I, Austin SF, Delouche C, Dollfus S, Erfurth A, Fleischhacker WW, Giordano GM, Gladyshev I, Glenthøj B, Gütter K, Hofer A, Hubeňák J, Kaiser S, Libiger J, Melle I, Nielsen MØ, Papsuev O, Rybakowski JK, Sachs G, Üçok A, Wojciak P, Galderisi S: A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale. *Eur Neuropsychopharmacol* 2019; 29(8): 947-59
- National Institute for Health and Care Excellence: CG178 Psychosis and schizophrenia in adults: treatment and management. UK: NICE, 2014
- Nuechterlein KH, Green MF, Kern RS, Baade LE et al: The MATRICS™ Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity. doi.org/10.1176/appi.ajp.2007.07010042 <https://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2007.07010042>
- de Pablo GS, Radua J, Pereira J, Bonoldi I, Arienti V, Besana F et al.: Probability of transition to psychosis in individuals at clinical high risk: an updated meta-analysis. *JAMA Psychiatry* 2021; 78(9): 970–978
- Patterson JV, Hetrick WP, Boutros NN et al.: P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. *Psychiatry Res* 2008; 158: 226-47.
- Perala J, Suvisaari J, Saarni SI et al.: Lifetime prevalence of psychotic and bipolar I disorders in a general population. *Arch Gen Psychiatry* 2007; 64: 19-28
- Petrides G, Malur C, Braga RJ, Bailine SH, Schooler NR, Malhotra AK, Kane JM, Sanghani S, Goldberg TE, John M, Mendelowitz A: Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. *Am J Psychiatry*. 2015; 172(1): 52-8
- Pitschel-Walz G, Leucht S, Bäuml J, Kissling W, Engel RR: The effect of family interventions on relapse and rehospitalization in schizophrenia--a meta-analysis. *Schizophr Bull* 2001; 27(1): 73-92
- Polderman TJC, Benyamin B, de Leeuw CA, Sullivan PF, van Bochoven A, Visscher PM, Posthuma D: Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nature Genetics* 2015; 47(7): 702-9
- Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. *Aust N Z J Psychiatry* 2016; 50(5): 1-117
- Rummel C, Kissling W, Leucht S: Antidepressants for the negative symptoms of schizophrenia. *Cochrane Database Syst Rev* 2006; (3):CD005581
- Sachs G, Volz HP: Neurokognition und Affektregulierung bei schizophrenen Psychosen. Schattauer 2012
- Sachs G, Winklbaur B, Jagsch R, Keefe RS.: Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results. *Eur Psychiatry* 2011; 26(2): 74-7

- Sachs G, Moser E, Katschnig H, Gur RC, Gur RE, Erfurth A: No amygdala attenuation in schizophrenic patients treated with atypical antipsychotics. *Psychiatry Res* 2012 31;202(2): 168-71
- Sachs G, Winklbaur B, Jagsch R, Lasser I, Kryspin-Exner I, Frommann N, Wölwer W: Training of affect recognition (TAR) in schizophrenia--impact on functional outcome. *Schizophr Res* 2012; 138(2-3): 262-7
- Sachs G, Volz HP (Hg): *Neurokognition und Affektregulierung bei schizophrenen Psychosen*. Klett-Cotta 2012
- Sachs G, Lasser I, Purdon SE, Erfurth A: Screening for cognitive impairment in schizophrenia: Psychometric properties of the German version of the Screen for Cognitive Impairment in Psychiatry (SCIP-G). *Schizophr Res Cogn* 2021; 25: 100197
- Sachs G, Kasper S, Aichhorn WJ, Aigner M, Di Pauli J, Erfurth A, Hajak G, Hofer A, Kapfhammer HP, Lehofer M, Marksteiner J, Psota G, Rados C, Silberbauer C, Willeit M: Stellenwert von Cariprazin in der Behandlung der Schizophrenie. *Update Europe. Internationale Zeitschrift für ärztliche Fortbildung* Nr. 17/Okttober 2021, ISSN 1726-0027
- Schizophrenia Working Group of the Psychiatric Genomics Consortium: Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 2014; 511(7510): 421-7
- Schultze-Lutter F, Addington J, Ruhrmann S, Klosterkötter J (2007) *Schizophrenia proneness instrument, adult version (SPI-A)*. Giovanni Fioriti Editore, Rome
- Schultze-Lutter F, Ruhrmann S, Fusar-Poli P, Bechdolf A, Schimmelmann BG, Klosterkötter J: Basic symptoms and the prediction of first-episode psychosis. *Curr Pharm Des* 2012; 18(4): 351-7
- Schultze-Lutter F, Marshall M, Koch E: *Schizophrenia proneness instrument, child and youth version; extended English translation (SPI-CY EET)*. Rome: Giovanni Fioriti Editore s.r.l; 2012
- Schultze-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RK, Riecher-Rössler A, van der Gaag M, Nordentoft M, Raballo A, Meneghelli A, Marshall M, Morrison A, Ruhrmann S, Klosterkötter J: EPA guidance on the early detection of clinical high risk states of psychoses. *Eur Psychiatry* 2015; 30(3): 405-16
- Spauwen J, Van Os J: The psychosis proneness: psychosis persistence model as an explanation for the association between urbanicity and psychosis. *Epidemiol Psychiatr Soc* 2006; 15(4): 252-7
- Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S, Kästner A, Skalej M, Jordan W, Schiltz K, Klingbeil C, Wandinger KP, Bogerts B, Stoecker W: Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encephalitis. *JAMA Psychiatry* 2013; 70(3): 271-8
- Tiihonen J, Wahlbeck K, Kiviniemi V: The efficacy of lamotrigine in clozapine-resistant schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2009; 109(1-3): 10-4
- Tiihonen J, Halonen P, Wahlbeck K, Repo-Tiihonen E, Hyvärinen S, Eronen M, Putkonen H, Takala P, Mehtonen OP, Puck M, Oksanen J, Koskelainen P, Joffe G, Aer J, Hallikainen T, Ryyänen OP, Tupala E: Topiramate add-on in treatment-resistant schizophrenia: a randomized double-blind placebo-controlled crossover trial. *J Clin Psychiatry* 2005; 66: 1012-5
- Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P: Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. *Arch Gen Psychiatry* 2012; 69(5): 476-83
- van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III. *Am J Psychiatry* 1998; 155(4): 565-7
- Van Os J, Pedersen CB, Mortensen PB: Confirmation of synergy between urbanicity and familial liability in the causation of psychosis. *Am J Psychiatry* 2004; 161(12): 2312-4

- Van Os J, Rutten BP, Poulton R: Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. *Schizophr Bull* 2008; 34(6): 1066-82
- Vita A, Gaebel W, Mucci A, Sachs G, Barlati S, Giordano GM, Nibbio G, Nordentoft M, Wykes T, Galderisi S: European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. *European Psychiatry* 2022; 65(1): e57, 1-16
- Vita A, Gaebel W, Mucci A, Sachs G, Erfurth A, Barlati S, Zanca F, Giordano GM, Birkedal Glenthøj L, Nordentoft M, Galderisi S: European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia. *European Psychiatry* 2022; 65(1): e58, 1-24
- Whitaker KJ, Vértes PE, Romero-Garcia R, Váša F, Moutoussis M, Prabhu G, Weiskopf N, Callaghan MF, Wagstyl K, Rittman T, Tait R, Ooi C, Suckling J, Inkster B, Fonagy P, Dolan RJ, Jones PB, Goodyer IM; NSPN Consortium Bullmore ET: Adolescence is associated with genomically patterned consolidation of the hubs of the human brain connectome. *Proc Natl Acad Sci USA* 2016; 113(32): 9105-10
- Wiedemann G, Klingberg S: Psychotherapy of positive symptoms in the treatment of patients with schizophrenia psychosis. *Nervenarzt* 2003; 74(1): 76-84
- Wohl M, Gorwood P: Paternal ages below or above 35 years old are associated with a different risk of schizophrenia in the offspring. *Eur Psychiatry* 2007; 22: 22-6
- Yung AR, Phillips LJ, Yuen HP, et al.: Risk factors for psychosis in an ultra-high-risk group: psychopathology and clinical features. *Schizophr Res* 2004; 67(2-3): 131-142
- Yung A, Yuen H, McGorry P, et al.: Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. *Aust N Z J Psychiatry* 2005; 39: 964-971